



## MAYNE PHARMA ANNOUNCES LEADERSHIP CHANGES

---

**16 January 2017, Adelaide Australia:** Mayne Pharma Group Limited (ASX: MYX) is pleased to announce a series of changes to the leadership team.

The key changes to the group leadership team are:

- **Stefan Cross**, former President of Mayne Pharma USA has been appointed as Chief Commercial Officer with responsibility for commercial product operations across the Group including Generic Products and Specialty Brands business units based in the US along with Australian commercial operations.
- **John Ross**, former EVP of Metrics Contract Services has been appointed as President, Mayne Pharma USA with responsibility for Metrics Contract Services and US operations including manufacturing, quality, supply chain and business integration.
- **Craig Boyd**, former EVP of Generic Products, has been appointed as Executive Vice President, Specialty Brands.
- **Gadi Ben-Nissim** has joined the leadership team as Executive Vice President, Generic Products.
- **Kimberly McClintock** has joined the leadership team as Executive Vice President, Metrics Contract Services.

Mayne Pharma's CEO Scott Richards said, "These leadership changes further strengthen the organisation introducing new talent while also improving alignment of key functions globally. Both Gadi and Kim will be valuable additions to the Mayne Pharma team with proven track records of success in the pharmaceutical industry. Gadi brings a broad range of commercial, operational, strategic and financial experience serving in a variety of senior management roles at Teva Pharmaceutical Industries Limited (Teva), including most recently leading the North American integration of the Teva/Allergan generics businesses. Kim has extensive experience in growing and leading contract development and manufacturing organisations whilst at Patheon Inc. and Alcami Corp. Her experience covers sales, business development, project management and research and development."

"The new roles for Stefan, John and Craig will leverage their experience both within Mayne Pharma as well as from their previous external roles. All three executives have been instrumental in overseeing the rapid development of the US businesses – Generic Products, Specialty Brands and Metrics Contract Services – which have together grown 5-fold over the last 3 years."

"These changes better align our senior leadership with the core growth drivers of the Group. John is a proven leader of pharma operations and has done an outstanding job over the last 3 years developing and growing Metrics Contract Services. I look forward to John expanding his influence on the business in this new expanded role. Stefan has been instrumental in establishing our US business over the last 3 years and will now focus his attention on accelerating the growth of our





## ASX Announcement

core revenue business units. Craig will bring his trademark energy and passion for sales and marketing excellence to the leadership of the Specialty Brands business.”

### About Gadi Ben-Nissim

Mr Ben-Nissim has spent the last 18 years at Teva in both regional and international roles across generics and specialty brands. In his last role at Teva he led the cross functional integration of the Actavis generics transaction in North America. His breadth of experience covers business unit leadership, commercial operations, marketing, portfolio management, product licensing, business strategy and M&A. Mr Ben-Nissim holds a Bachelor of Science in Industrial Engineering from Technion in Israel and a MBA from Inter Disciplinary Institution (IDC) in Israel.

### About Kimberly McClintock

Ms McClintock has more than 18 years of experience in the pharmaceutical industry across sales, business development, project management and research and development. Prior to joining Mayne Pharma, she led the Drug Product and Lab Services Business Unit as Senior Director at Alcami Corp, a leading global provider of contract development and manufacturing services. She also held several management roles at Banner Pharmacaps (division of Patheon). Ms McClintock holds a Bachelor of Arts in Chemistry from North Carolina State University and a MBA from the University of North Carolina.

### For further information contact:

Scott Richards +61 8 8209 2410

Lisa Pendlebury +61 419 548 434, [lisa.pendlebury@maynepharma.com](mailto:lisa.pendlebury@maynepharma.com)

### About Mayne Pharma

*Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.*

*Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.*

*Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.*

